Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties

Journal of Pharmaceutical Sciences

Volumn 98, Issue 4, 2009, Pages 1463-1475

  Pilcer, Gabrielle ^a   Vanderbist, Francis ^b   Amighi, Karim ^a,c  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b SMB SA   (Belgium)

^c Campus de la Plaine ^*  (Belgium)

Author keywords

Amorphous; Carrier free; Dry powder inhaler (dpi); Pulmonary delivery; Spray drying; Tobramycin

Indexed keywords

2 PROPANOL; TOBRAMYCIN; WATER;

AEROSOL; ARTICLE; CHEMICAL STRUCTURE; DENSITY; DISPERSION; DRUG FORMULATION; DRY POWDER; INHALATION; LASER DIFFRACTION; PARTICLE SIZE; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SUSPENSION; TEMPERATURE; WATER CONTENT; X RAY POWDER DIFFRACTION;

EID: 67449168070     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21545     Document Type: Article

References (26)

1. Adi H, Young PM, Chan HK, Stewart P, Agus H, Traini D, 2008. Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci 97:3556- 3566.
2. Newhouse M, Hirst P, Duddu S, Walter Y, Tarara T, Clarck A, Weers J. 2003. Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers. Chest 124:360-366.
3. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, Ramsey BW, The Aerosolized Tobramycin Study Group. 1997. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebuliser systems. Chest 111:955-962.
4. Irngartinger M, Camuglia V, Damn M, Goede J, Frijlink IIW. 2004. Pulmonary delivery of therapeutic peptides via dry powder inhalation: Effects of micronisation and manufacturing. Eur J Pharm Biopharm 58:7-14.
5. Vanderbist F, Wery B, Moyano-Pavon I, Moës AJ, 1999. Optimization of a dry powder inhaler formulation of nacystelyn, a new mucoactive agent. J Pharm Pharmacol 51:1229-1234.
6. Weers JG. 2000. Dispersible powders for inhalation applications. Innov Pharm Technol 1:111-116.
7. Martin GP, MacRithie HB, Marriott C, Zeng XM. 2006. Characterisation of a carrier-free dry powder aerosol formulation using inertial impaction and laser diffraction. Pharm Res 23:2210-2219.
8. Wetterlin K. 1988. Turbuhaler: A new powder inhaler for administration of drugs to the airways. Pharm Res 5:506-508.
9. Telko MJ, Hickey AJ. 2005. Dry powder inhaler formulation. Respir Care 50:1209-1227.
10. Rehman M, Shekunov BY, York P, Lechuga-Balles- teros D, Miller DP, Tan T, Colthorpe P. 2004. Optimisation of powders for pulmonary delivery using supercritical fluid technique. Eur J Pharm Sci 22:1-17.
11. Chan HK, Chew NYK. 2003. Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv Drug Deliv Rev 55:793-805.
12. Rabbani NR, Seville PC. 2005. The influence of formulation components on the aerosolisation properties of spray-dried powders. J Control Release 110:130-140.
13. Sacchetti M, Van Oort MM. 1996. Spray drying and supercritical fluid particle generation techniques. In: Hickey AJ, editor. Inhalation aerosols: Physical and biological basis for therapy. New-York: Marcel Dekker. pp 337-384.
14. Chawla A, Taylor KMG, Newton JM, Johnson MGR. 1994. Production of spray dried salbutamol sulphate for use in dry powder formulation. Int J Pharm 108:233-240.
15. Vidgren MT, Vidgren PA, Paronen TP. 1987. Comparison of physical and inhalation properties of spray-dried and mechanically micronized disodium cromoglycate. Int J Pharm 35:139-144.
16. Bosquillon C, Preat V, Vanbever R. 2004. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J Control Release 96:233-244.
17. Duddu SP, Sisk SA, Walter YH, Tarrara TE, Trimble KR, Clark AR, Eldon MA, Elton RC, Pickford M, Hirst PH, Newman SP, Weers JG. 2002. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere powder. Pharm Res 19:689-695.
18. Zilstra GS, Hinrichs WLJ, de Boer AH, Frijnlink HW. 2004. The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix. Eur J Pharm Sci 23:139- 149.
19. Johnson KA. 1997. Preparation of peptide and protein powders for inhalation. Adv Drug Deliv Rev 26:3-15.
20. Pilcer G, Sebti Th, Amighi K. 2006. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res 23:931-940.
21. Pilcer G, Vanderbist F, Amighi K. 2008. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations. Int J Pharm 358:75-81.
22. Israelachvili JN. 1991. Intermolecular and surface forces, 2nd edition. London: Academic Press.
23. Crowder TM. 2003. A guide to pharmaceutical particulate science. Boca Raton, Florida: Interpharm Press/CRC.
24. Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. 2007. Particle engineering for pulmonary drug delivery. Pharm Res 24:411-437.
25. Elversson J, Millqvist-Fureby A, Alderborn G, Elofsson U. 2003. Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray-drying. J Pharm Sci 92: 900-910.
26. Steckel H, Brandes HG. 2004. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int J Pharm 278:187-195.